AURORA, Colo., Feb. 18, 2020 /PRNewswire/ -- Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on precision medicine cancer therapies, was featured in an interview by CEOCFO Magazine. The article with a title: "New class of Cancer Therapeutics, RAL GTPase Inhibitors Show Potential to Inhibit Tumor Growth and Metastasis in KRAS Mutant Cancers that Represent 30% of All Cancers" was published on February 17, 2020, and brings in-depth interviews between the CEO of Machavert, Dr. Jakub Staszak-Jirkovsky, and the senior editor Lynn Fosse.
The interview focused on core technology currently developed at Machavert and its possible impact on the treatment of cancer. Namely, the company is dedicating 100% of our drug development efforts on the RAL inhibitor program. We have successfully shown in animal efficacy experiments that Machavert's lead molecule, MP2018 is efficacious in KRAS G12C pancreatic cancer models and also non-small cell lung carcinoma (NSCLC) models and we are continuing our effort down a well-planed drug development path with our lead compound for these two indications. Further, we are aiming at demonstrating the wide therapeutic potential of RAL GTPase inhibition on multiple KRAS mutations and to its expected specialty, control of tumor spread and metastases. The full interview can be accessed here: https://www.ceocfointerviews.com/machavertpharmaceuticals20.html
About Machavert Pharmaceuticals
Machavert Pharmaceuticals is a preclinical stage drug development company focused on precision medicine based on small molecule RAL GTPase inhibitors against KRAS cancers in hematology and solid tumor oncology.
For further information: Jakub Staszak-Jirkovsky, Chief Executive Officer, Machavert Pharmaceuticals, 720.859.4048, [email protected]
SOURCE Machavert Pharmaceuticals